Clinical momentum TuHURA is a Phase 3 immuno-oncology company focusing on overcoming resistance to cancer immunotherapy with advancing programs such as TBS-2025, a VISTA-inhibiting mAb moving into Phase 1b dose escalation for mutNPM1 relapsed/refractory AML, signaling near-term translational milestones and potential advisory/sponsored collaboration opportunities.

Biologic portfolio Beyond innate immune agonists, the company is developing bispecific and bi-functional antibody drug conjugates (ADCs) targeting myeloid suppression (MDSCs) to prevent T cell exhaustion, which creates multiple avenues for partnership in novel IO modalities and companion diagnostics.

Delta Opioid leverage TuHURA’s Delta Opioid Receptor technology aims to enhance checkpoint inhibitor efficacy by mitigating MDSC-driven immunosuppression, presenting a compelling value proposition for alliances with larger oncology developers seeking next‑gen immune modulation assets.

Strategic visibility Active investor engagement and conference participation, including Canaccord Genuity and H.C. Wainwright events, indicate a readiness for deal-making, licensing discussions, and potential co-development or funding collaborations with biotech and pharma partners.

Financial profile With a modest revenue base and total funding around forty-seven million dollars, TuHURA appears positioned for early-stage collaborations, milestone-driven partnerships, and strategic out-licensing of its first-in-class immuno-oncology assets to accelerate clinical and commercial milestones.